| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.14 | 0.4 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | JQ-1:vorinostat (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |